Moffitt Notice of Blackbaud Data Incident. Learn More
Clinical Trials Search
Phase I Study of APR-246 in Combination with Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies
This clinical trial is a Phase I, open-label, dose-finding and cohort expansion study to determine the safety and preliminary efficacy of APR-246 in combination with venetoclax and azacitidine in patients with myeloid malignancies.
To evaluate the safety and tolerability of administration of APR-246 in combination with venetoclax and azacitidine in patients with TP53-mutant myeloid malignancies.
APR-246 (); GDC-0199 (Venetoclax); Venetoclax (); azacitidine (5-azacitidine)